Myelomastocytic leukemia: Evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation

Clinical Cancer Research

Volumn 11, Issue 19 I, 2005, Pages 6787-6792

  Sperr, Wolfgang R ^a   Drach, Johannes ^a   Hauswirth, Alexander W ^a   Ackermann, Jutta ^a   Mitterbauer, Margit ^a   Mitterbauer, Gerlinde ^a   Foedinger, Manuela ^a   Fonatsch, Christa ^a   Simonitsch Klupp, Ingrid ^a   Kalhs, Peter ^a   Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; TRANSCRIPTION FACTOR RUNX1; TRYPTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHROMOSOME TRANSLOCATION; CLONAL VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HUMAN; HUMAN CELL; KARYOTYPE; MALE; MALIGNANT TRANSFORMATION; MAST CELL; MASTOCYTOSIS; MYELOID LEUKEMIA; MYELOMASTOCYTIC LEUKEMIA; PRIORITY JOURNAL;

ADOLESCENT; ANTIGENS, CD2; ANTIGENS, CD34; BONE MARROW CELLS; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; FLOW CYTOMETRY; GRANULOCYTE PRECURSOR CELLS; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MAST CELLS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, INTERLEUKIN-2; SERINE ENDOPEPTIDASES; STEM CELL TRANSPLANTATION; TRANSLOCATION, GENETIC; TRANSPLANTATION, HOMOLOGOUS; TRYPTASES; TUMOR MARKERS, BIOLOGICAL;

EID: 26444578394     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1064     Document Type: Article

References (33)

1. Valent P, Spanblöchl E, Bankl HC, et al. Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis. Blood 1994; 84:4322-32.
2. Wimazal F, Sperr WR, Horny HP, et al. Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells. Am J Hematol 1999; 61:66-77.
3. Valent P, Sperr WR, Samorapoompichit P, et al. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. Leuk Res 2001;25:595-602.
4. Valent P, Samorapoompichit P, Sperr WR, Horny HP, Lechner K. Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J 2002;3: 90-4.
5. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-25.
6. Valent P, Horny HP, Li CY, et al. Mastocytosis, in Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classification of tumors, pathology and genetics of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. p. 291-302.
7. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001;25:543-51.
8. Prokocimer M, Polliack A. Increased bone marrow mast cells in preleukemic syndromes, acute leukemia, and lymphoproliferative disorders. Am J Clin Pathol 1981;75:34-8.
9. Sperr WR, Horny HP, Lechner K, et al. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk Lymphoma 2000; 37:473-86.
10. Sperr WR, Horny HP, Valent P. Spectrum of associated clonal hematologic non-mast cell lineage disorders occurring in patients with systemic mastocytosis. Int Arch Allergy Immunol 2002;127: 140-2.
11. Bernd HW, Sotlar K, Lorenzen J, et al. Acute myeloid leukaemia with t(8;21) associated with "occult" mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol 2004;57:324-8.
12. Travis WD, Li CY, Hoagland HC, et al. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 1986;61:957-66.
13. Worobec AS. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000;14: 659-87.
14. Valent P, Akin C, Sperr WR, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003;27:635-41.
15. Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003;122:695-717.
16. Schernthaner GH, Jordan JH, Ghannadan M, et al. Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. Blood 2001;98:3784-92.
17. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001;98:2200-9.
18. Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998;22: 1132-40.
19. Jordan JH, Walchshofer S, Jurecka W, et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 2001;32:545-52.
20. Kaufmann H, Ackermann J, Nosslinger T, et al. Absence of clonal chromosomal relationship between concomitant B-CLL and multiple myeloma-a report on two cases. Ann Hematol 2001;80:474-8.
21. Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995;86:3915-21.
22. Kusec R, Laczika K, Knöbl P, et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994;8:735-9.
23. Sperr WR, Escribano L, Jordan JH, et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001;25: 529-36.
24. Longley BJ, Tyrrell L, Lu SZ, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12: 312-4.
25. Longley BJ, Jr., Metcalfe DD, Tharp M, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 1999;96: 1609-14.
26. Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998;91:2731-6.
27. Sperr WR, Walchshofer S, Horny HP, et al. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br J Haematol 1998;103:740-9.
28. Chen TY, Chen JS, Huang WT, et al. Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant 2003;32:111-4.
29. Pullarkat VA, Bueso-Ramos C, Lai R, et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003;73:12-7.
30. Sotlar K, Marafioti T, Griesser H, et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol 2000;53:188-93.
31. Sotlar K, Fridrich C, Mall A, et al. Detection of c-kit point mutation Asp-816 → Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002; 26:979-84.
32. Födinger M, Fritsch G, Winkler K, et al. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 1994;84: 2954-9.
33. Sperr WR, Hauswirth AW, Valent P. Tryptase a novel biochemical marker of cute myeloid leukemia. Leuk Lymphoma 2002;43:2257-61.